Toronto Centre

ZYUS Strengthens Expertise of Clinical Advisory Committee with the Appointment of Dr. Hance Clarke

Retrieved on: 
Thursday, February 1, 2024
Science, Other Science, Research, Natural Resources, Pharmaceutical, Alternative Medicine, Health, Cannabis, Knowledge, School, Chronic pain, Hospital, Faculty, Patient, FRCPC, Public health, Toronto General Hospital, Advisory Committee, Knowledge translation, Medical school, Entrepreneurship, Queen Elizabeth, Consortium, Assistant, Pain management, Drug development, Risk, Anesthesiology, Toronto Centre, Doctor of Philosophy, University, Committee, Medicine, Pharmaceutical industry

ZYUS Life Sciences Corporation (the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company leading scientific research and global development of innovative cannabinoid-based pharmaceutical drug products, today announced the appointment of Hance Clarke, MD, PhD, FRCPC to ZYUS Life Sciences Inc.’s Clinical Advisory Committee.

Key Points: 
  • ZYUS Life Sciences Corporation (the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company leading scientific research and global development of innovative cannabinoid-based pharmaceutical drug products, today announced the appointment of Hance Clarke, MD, PhD, FRCPC to ZYUS Life Sciences Inc.’s Clinical Advisory Committee.
  • Dr. Clarke is internationally recognized for his outstanding contributions to research productivity and advancements in patient care.
  • "We are pleased to announce the appointment of Dr. Hance Clarke to the Clinical Advisory Committee," said Brent Zettl, President and CEO of the Company.
  • This strategic addition to our Clinical Advisory Committee reaffirms ZYUS’ commitment to advancing non-opioid-based therapies as a viable alternative for managing pain.”
    "I am honored to join ZYUS’ Clinical Advisory Committee and eager to contribute to ZYUS’ important work.

Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis

Retrieved on: 
Monday, November 13, 2023
Primary biliary cholangitis, Hepatology, SAN, Myofibroblast, Therapy, PSC, Primary sclerosing cholangitis, PBC, Cirrhosis, AASLD, Toronto Centre, ALK5, Patient, Wound healing, Liver disease, Gene expression, TGF, Liver, Non-alcoholic fatty liver disease, Fibrosis, Trial of the century, ELF, Integrin, Safety, Pharmaceutical industry

These posters were presented at The Liver Meeting® 2023 of the American Association for the Study of Liver Diseases (AASLD).

Key Points: 
  • These posters were presented at The Liver Meeting® 2023 of the American Association for the Study of Liver Diseases (AASLD).
  • “Our presentations at the Liver Meeting feature preclinical and clinical work supportive of bexotegrast’s antifibrotic mechanism of action in liver fibrosis,” said Éric Lefebvre, M.D., Chief Medical Officer of Pliant.
  • An αVβ1-selective integrin inhibitor was evaluated on fibrotic and non-fibrotic human liver tissue to assess the effects on cell populations present in fibrotic human liver tissue.
  • The effects of bexotegrast (PLN-74809), a dual inhibitor of integrins αVβ6 and αVβ1, were assessed on human liver tissue to characterize the response of unique cell populations in fibrotic primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC).

Dr. Jinzi J. Wu Presents at the 10th International Workshop on HBV Cure 2023

Retrieved on: 
Thursday, November 9, 2023
Massachusetts General Hospital, Patient, HKEX, Research, PD-L1, Hepatitis B virus, Trial of the century, Harvard Medical School, AIDS, National Institutes of Health, Lim, Johns Hopkins University, Arbutus, Prevalence, Jacob Aligo, Safety, PD-1, University of Milan, CHB, University of Hong Kong, Virus, Phase, Immunotherapy, Risk, HIV/AIDS research, International Workshop on Lung Health, Bangladesh Technical Education Board, GSK, University, Roche, HBsAg, VIR, University of Oxford, Toronto Centre, Liver disease, HBV, Hook effect, Village Vanguard Live Sessions 3, Vaccine, Pharmaceutical industry, Northwestern University, Immunocore

HANGZHOU and SHAOXING, China, Nov. 8, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that Dr. Jinzi J. Wu, Founder, Chairman and CEO of Ascletis was invited to attend and have a presentation at the 10th International Workshop on HBV Cure 2023 held at Boston, United States.

Key Points: 
  • HANGZHOU and SHAOXING, China, Nov. 8, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that Dr. Jinzi J. Wu, Founder, Chairman and CEO of Ascletis was invited to attend and have a presentation at the 10th International Workshop on HBV Cure 2023 held at Boston, United States.
  • The interim analysis included 25 patients who completed 24-week treatment (19 patients in ASC22 cohort and 6 patients in placebo cohort).
  • Topline results indicated that in ASC22 cohort, 4 patients (4/19, 21.1%) achieved HBsAg loss at the end of 24-week treatment.
  • "It's a great honor to be invited to the 10th International Workshop on HBV Cure 2023 and share our latest progress in developing the immune checkpoint inhibitor for functional cure of CHB with the global industry.

Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023

Retrieved on: 
Thursday, October 19, 2023
Patient, FDA, Publication, Therapy, UDCA, Hepatology, Cirrhosis, ELF, Safety, Liver, Fibrosis, Primary sclerosing cholangitis, Idiopathic pulmonary fibrosis, Liver disease, Inflammation, HIV disease progression rates, IPF, PSC, Pharmacokinetics, Ursodeoxycholic acid, American Association for the Study of Liver Diseases, Disease, EMA, Liver failure, Integrin, Toronto Centre, Abstract, Inflammatory bowel disease, Non-alcoholic fatty liver disease, SAN, AASLD, Pharmaceutical industry, Vaccine, Medical imaging

The oral presentation titled “Oral αvβ6/αVβ1 Integrin Inhibition in Primary Sclerosing Cholangitis: 12-week Interim Safety and Efficacy Analysis of INTEGRIS-PSC, A Phase 2a Trial of Bexotegrast,” will be delivered by Professor Gideon Hirschfield, M.D., Lily and Terry Horner Chair in Autoimmune Liver Disease Research, Toronto Centre for Liver Disease.

Key Points: 
  • The oral presentation titled “Oral αvβ6/αVβ1 Integrin Inhibition in Primary Sclerosing Cholangitis: 12-week Interim Safety and Efficacy Analysis of INTEGRIS-PSC, A Phase 2a Trial of Bexotegrast,” will be delivered by Professor Gideon Hirschfield, M.D., Lily and Terry Horner Chair in Autoimmune Liver Disease Research, Toronto Centre for Liver Disease.
  • PSC is a rare, progressive liver disease of unknown origin, which frequently occurs in the setting of inflammatory bowel disease.
  • PSC is characterized by inflammation and fibrosis, with progressive liver and biliary damage leading to cirrhosis and liver failure.
  • Exploratory endpoints will measure changes in liver fibrosis markers, ELF and PRO-C3, liver biochemistry and liver imaging.

CymaBay’s RESPONSE Phase 3 Data Evaluating Seladelpar for Primary Biliary Cholangitis to be Featured in an Oral Late-Breaking Presentation at The Liver Meeting® 2023

Retrieved on: 
Wednesday, October 18, 2023
Randomness, American Association for the Study of Liver Diseases, Hepatology, Liver, Congress, Conditional sentence, Safety, Placebo-controlled study, PBC, Obeticholic acid, Research and development, Primary biliary cholangitis, Toronto Centre, Therapy, Liver disease, Abstract, Liver support system, AASLD, Pharmaceutical industry, Patient, Research

NEWARK, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that a late-breaking presentation highlighting results from the RESPONSE Phase 3 study of seladelpar in patients with primary biliary cholangitis (PBC) will be presented at The Liver Meeting® of the American Association for the Study of Liver Diseases (AASLD), in Boston, MA (November 10th – 14th). Seladelpar is a potent, selective, orally active delpar or PPARδ agonist, in development for the treatment of adult patients with primary biliary cholangitis (PBC).

Key Points: 
  • Seladelpar is a potent, selective, orally active delpar or PPARδ agonist, in development for the treatment of adult patients with primary biliary cholangitis (PBC).
  • The oral presentation titled “Efficacy and Safety of Seladelpar in Patients with Primary Biliary Cholangitis in the RESPONSE Trial: A Phase 3 International, Randomized, Placebo-Controlled Study,”1 will be delivered by Professor Gideon Hirschfield, M.D., Lily and Terry Horner Chair in Autoimmune Liver Disease Research, Toronto Centre for Liver Disease.
  • We are extremely grateful to our team, investigators, and especially patients in the participation and collaboration in this endeavor.
  • Presentations at the Liver Meeting® 2023 include:
    1“Efficacy and Safety of Seladelpar in Patients with Primary Biliary Cholangitis in the RESPONSE Trial: A Phase 3 International, Randomized, Placebo-Controlled Study” (Abstract #5002)
    Congress attendees can visit CymaBay throughout the meeting at booth D3034.

Heart to Heart CPR Now Offering Free Naloxone Kits and Opioid Response Training to Communities Most in Need!

Retrieved on: 
Friday, March 31, 2023
Travel, Peer support, Education, Canadian Red Cross, Toronto Centre, Naloxone, Oxygen, COVID-19, Collaboration, Opioid, FREE, Red, Movement, Parliament, Death, PPE, Social isolation, Risk, MP, CPR, Mental health, News, Nursing, Pharmaceutical industry, Medical device, Heart, Woman

Heart to Heart CPR will be providing FREE naloxone kits and opioid poisoning response training to their community.

Key Points: 
  • Heart to Heart CPR will be providing FREE naloxone kits and opioid poisoning response training to their community.
  • Heart to Heart has been a training partner for the Canadian Red Cross for 24 years.
  • With 16 training locations across Ontario, they are leaders in first aid and CPR education and training.
  • We will slowly roll out this program across all Heart to Heart locations," says Nick Rondinelli, CEO of Heart to Heart CPR .

Canada-in-Asia Conference Arrives in Singapore February 21-23, 2023

Retrieved on: 
Tuesday, February 14, 2023
Organization, Government of Canada, Asia Pacific Foundation of Canada, CIBC, The Business Council, Investissement Québec, McMillan, University of Saskatchewan, Greater East Asia Conference, University of Calgary, Toronto Centre, University of British Columbia, Government of Saskatchewan, Universities Canada, University, York University, Business Council of Canada, Fairmont, Royal Bank, McCarthy, Parable of those who associate partners with God, McGill University, C100, Research, McMillan LLP, University of Toronto, Royal Bank of Canada, Air Canada, Sun Life Financial, BMO, Partner, Gouvernment of Atjeh and Dependencies, University of Ottawa, Export Development Canada, Conference, 2020 Toronto Centre federal by-election, Western University, Oil, Bombardier

VANCOUVER, British Columbia, Feb. 13, 2023 (GLOBE NEWSWIRE) -- The Asia Pacific Foundation of Canada (APF Canada) and Universities Canada are excited to announce the inaugural Canada-in-Asia Conference 2023, being held in Singapore on February 21-23, 2023.

Key Points: 
  • VANCOUVER, British Columbia, Feb. 13, 2023 (GLOBE NEWSWIRE) -- The Asia Pacific Foundation of Canada (APF Canada) and Universities Canada are excited to announce the inaugural Canada-in-Asia Conference 2023, being held in Singapore on February 21-23, 2023.
  • Over two days at the Fairmont Singapore’s Raffles City Convention Centre, the conference program combines keynote and inter‑disciplinary plenary sessions, high-level thematic panel discussions, strategic networking opportunities, and an evening gala.
  • The Canada-in-Asia Conference is presented with the assistance of the Government of Canada.
  • APF Canada and Universities Canada would also like to thank our in-kind partners: the C100, Mila, the Toronto Centre, the Business Council of Canada, and the Canada-ASEAN Business Council.

New England Journal of Medicine Publishes Positive Phase 3 TOGETHER Results with Peginterferon Lambda in COVID-19

Retrieved on: 
Wednesday, February 8, 2023
SARS-COV-2, Toronto, HDV, Vaccine, SARS-CoV-2, Ottawa Hospital Research Institute, NEJM, Hospital, Toronto Centre, Patient, Vaccination, Safety, Liver disease, Pontifical Catholic University of Campinas, Risk, Incidence, Clinical trial, RNA, Interim, University, The New England Journal of Medicine, PALO, Mortality, University of Toronto, Hepatitis, Associate, Death, Manuscript, Antibody, MPH, Peginterferon-alfa, Eiger, COVID-19, ISCB Senior Scientist Award, Doctor of Philosophy, Pharmaceutical industry, Medicine, MD

PALO ALTO, Calif., Feb. 8, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced the publication of data from the investigator-sponsored Phase 3 TOGETHER study in patients with COVID-19 in the New England Journal of Medicine (NEJM). The study, which evaluated newly diagnosed outpatients with mild-to-moderate COVID-19, found that among predominantly vaccinated participants with COVID-19, a single-dose treatment with Eiger's investigational agent, peginterferon lambda, resulted in significantly decreased clinical events. The manuscript titled "Effect of Early Treatment with Pegylated Interferon Lambda among COVID-19 Patients" will be published in the February 9, 2023 issue of NEJM and follows the topline safety and efficacy data announced March 17 2022.

Key Points: 
  • The treatment effect for peginterferon lambda was more pronounced in patients who were treated within 3 days of symptom onset.
  • Incidence of any treatment emergent adverse events was similar between peginterferon lambda and placebo groups, which were primarily injection site reactions.
  • "We have over 100,000 peginterferon lambda syringes readily available with additional manufacturing intermediates to support a capacity of >10 million units if needed.
  • In the context of our ongoing portfolio prioritization process, we continue to explore opportunities for ex-US emergency use of peginterferon lambda for COVID-19."

Canada-in-Asia Conference Arrives in Singapore February 21-23, 2023

Retrieved on: 
Monday, February 6, 2023
Toronto Centre, Government of Canada, Partner, University of Calgary, Research, University, The Business Council, University of Ottawa, McGill University, McMillan LLP, Royal Bank, Greater East Asia Conference, McMillan, Government, Fairmont, Universities Canada, BMO, 2020 Toronto Centre federal by-election, Conference, University of Toronto, CIBC, Asia Pacific Foundation of Canada, C100, Business Council of Canada (BCC), Politics of Saskatchewan, University of Saskatchewan, York University, Royal Bank of Canada, McCarthy, Organization, Parable of those who associate partners with God, Western University, Investissement Québec, University of British Columbia, Export Development Canada, Sun Life Financial, Video game, Oil, Bombardier

VANCOUVER, British Columbia, Feb. 05, 2023 (GLOBE NEWSWIRE) -- The Asia Pacific Foundation of Canada (APF Canada) and Universities Canada are excited to invite members of the media to the inaugural Canada-in-Asia Conference 2023 in Singapore on February 21-23, 2023.

Key Points: 
  • VANCOUVER, British Columbia, Feb. 05, 2023 (GLOBE NEWSWIRE) -- The Asia Pacific Foundation of Canada (APF Canada) and Universities Canada are excited to invite members of the media to the inaugural Canada-in-Asia Conference 2023 in Singapore on February 21-23, 2023.
  • “Our alumni in Asia act as ambassadors for that work, and for Canada.
  • The Canada-in-Asia Conference is presented with the assistance of the Government of Canada.
  • APF Canada and Universities Canada would also like to thank our in-kind partners: the C100, Mila, the Toronto Centre, and the Business Council of Canada.

Entrepreneurship and urban research the focus of new centre launched in Mumbai by University of Toronto with Tata Trusts

Retrieved on: 
Wednesday, February 1, 2023
Toronto Centre, University of Toronto, Entrepreneurship, U of T, Sir Ratan Tata Trust, Poverty, Water, Partnership, University, Mail order, Creative industries, Pharmaceutical industry

Toronto, Feb. 01, 2023 (GLOBE NEWSWIRE) -- The University of Toronto launched The University of Toronto Centre in India today in Mumbai in partnership with Tata Trusts, one of India’s largest philanthropic organizations.

Key Points: 
  • Toronto, Feb. 01, 2023 (GLOBE NEWSWIRE) -- The University of Toronto launched The University of Toronto Centre in India today in Mumbai in partnership with Tata Trusts, one of India’s largest philanthropic organizations.
  • Tata Trusts has been a longstanding collaborator with U of T, supporting researchers across the university to address health care, water, energy and poverty challenges.
  • The new centre will give focus to this collaboration with an emphasis on urban research and entrepreneurship, bringing together leading scholars and innovators from Canada and India to develop ground-breaking research and innovation to benefit people in India and around the world.